Obesity and Free Fatty Acids

Endocrinology and Metabolism Clinics of North America

Volumn 37, Issue 3, 2008, Pages 635-646

  Boden, Guenther ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; FATTY ACID; INSULIN; MATRIX METALLOPROTEINASE;

ATHEROSCLEROSIS; BLOOD CLOTTING DISORDER; CARDIOVASCULAR RISK; DYSLIPIDEMIA; FATTY ACID BLOOD LEVEL; FATTY ACID METABOLISM; FIBRINOLYSIS; HORMONAL REGULATION; HUMAN; HYPERINSULINEMIA; HYPERTENSION; INFLAMMATION; INSULIN RESISTANCE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; ATHEROSCLEROSIS; FATTY ACIDS, NONESTERIFIED; HUMANS; INFLAMMATION; INSULIN RESISTANCE; MATRIX METALLOPROTEINASES; METABOLIC SYNDROME X; OBESITY;

EID: 50449086746     PISSN: 08898529     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ecl.2008.06.007     Document Type: Review

References (60)

1. Boden G. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes 46 (1997) 3-10
2. Tataranni P.A., and Ortega E.A. Burning question. Does an adipokines-induced activation of the immune system mediate the effect of overnutrition on type 2 diabetes?. Diabetes 54 (2005) 917-927
3. Bray G.A. Medical consequences of obesity. J Clin Endocrinol Metab 89 (2004) 2583-2589
4. Kershaw E.E., and Flier J.S. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 89 (2004) 2548-2556
5. Reaven G.M., Hollenbeck C., Jeng C.-Y., et al. Measurement of plasma glucose, free fatty acid, lactate and insulin for 24 h in patients with NIDDM. Diabetes 37 (1988) 1020-1024
6. Boden G., Chen X., Ruiz J., et al. Mechanisms of fatty acid-induced inhibition of glucose uptake. J Clin Invest 93 (1994) 2438-2446
7. Santomauro A.T.M.G., Boden G., Silva M., et al. Overnight lowering of free fatty acids with acipimox improves insulin resistance and glucose tolerance in obese diabetic and nondiabetic subjects. Diabetes 48 (1999) 1836-1841
8. Bjorntorp P., Bergman H., and Varnauskas E. Plasma free fatty acid turnover in obesity. Acta Med Scand 185 (1969) 351-356
9. Jensen M.D., Haymond M.W., Rizza R.A., et al. Influence of body fat distribution on free fatty acid metabolism in obesity. J Clin Invest 83 (1989) 1168-1173
10. Boden G., and Chen X. Effects of fat on glucose uptake and utilization in patients with non-insulin-dependent diabetes. J Clin Invest 96 (1995) 1261-1268
11. Boden G., Jadali F., White J., et al. Effects of fat on insulin stimulated carbohydrate metabolism in normal men. J Clin Invest 88 (1991) 960-966
12. Rizza R.A., Mandarino L.J., and Gerich J.E. Dose-response characteristics for effects of insulin on production and utilization of glucose in man. Am J Phys 240 (1981) E630-E639
13. Boden G., Cheung P., Stein T.P., et al. FFA cause hepatic insulin resistance by inhibiting insulin suppression of glycogenolysis. Am J Phys 283 (2002) E12-E19
14. Baron A.D. Insulin resistance and vascular function. J Diabet Complications 16 (2002) 92-102
15. Zeng G., Nystrom F.H., Ravichandran L.V., et al. Roles for insulin receptor, PI3-kinase and Akt in insulin-signaling pathways related to production of nitric oxide in human vascular endothelial cells. Circulation 101 (2000) L1539-L1545
16. Steinberg H.O., Tarshoby M., Monestel R., et al. Elevated circulating free fatty acid levels impair endothelium-dependent vasodilation. J Clin Invest 100 (1997) 1230-1239
17. Cusi K., Kashyap S., Gastaldelli A., et al. Effect on insulin secretion and insulin action of a 48-h reduction of plasma free fatty acids with acipimox in nondiabetic subjects genetically predisposed to type 2 diabetes. Am J Physiol Endocrinol Metab 292 (2007) E1775-E1781
18. Dresner A., Laurent D., Marcucci M., et al. Effects of free fatty acids on glucose transport and IRS-1 associated phosphatidylinositol 3-kinase activity. J Clin Invest 103 (1999) 253-259
19. Boden G., Lebed B., Schatz M., et al. Effects of acute changes of plasma free fatty acids on intramyocellular fat content and insulin resistance in healthy subjects. Diabetes 50 (2001) 1612-1617
20. Itani S.I., Ruderman N.B., Schmieder F., et al. Lipid-induced insulin resistance in human muscle is associated with changes in diacylglycerol, protein kinase C, and IκB-α. Diabetes 51 (2002) 2005-2011
21. Farese R. Diabetes mellitus: a fundamental and clinical text. In: LeRoith D., Taylor S.I., and Olefsky J.M. (Eds) (2000), Lippincott, Philadelphia p. 239-51
22. Boden G., She P., Mozzoli M., et al. Free fatty acids produce insulin resistance and activate the proinflammatory nuclear factor-κB pathway in rat liver. Diabetes 54 (2005) 3458-3465
23. Hotamisligil G.S. Role of endoplasmic reticulum stress and c-Jun NH2-terminal kinase pathways in inflammation and origin of obesity and diabetes. Diabetes 54 (2005) S73-S78
24. Inoguchi T., Li P., Umeda F., et al. High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C-dependent activation of NAD(P)H oxidase in cultured vascular cells. Diabetes 49 (2000) 1939-1945
25. Shi A., Kokoeva V., Inouye K., et al. TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest 116 (2006) 3015-3025
26. Yu C., Chen Y., Cline G.W., et al. Mechanism by which fatty acids inhibit activation of insulin receptor substrate-1 (IRS-1)-associated phosphatidylinositol 3-kinase activity in muscle. J Biol Chem 277 (2002) 50230-50236
27. Saltiel A.R., and Kahn C.R. Insulin signaling and the regulation of glucose and lipid metabolism. Nature 414 (2001) 799-806
28. Long S.D., and Pekala P.H. Regulation of Glut4 gene expression by arachidonic acid. Evidence for multiple pathways, one of which requires oxidation to prostaglandin. European Journal of Biological Chemistry 271 (1996) 1138-1144
29. Armoni M., Harel C., Bar-Yoseph F., et al. Free fatty acids repress the Glut4 gene expression in cardiac muscle via novel response elements. J Biol Chem 280 (2005) 34786-34795
30. Xu H., Barnes G.T., Yang Q., et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 112 (2003) 1821-1830
31. van Oostrom A.J., van Dijk H., Verseyden C., et al. Addition of glucose to an oral fat load reduces postprandial free fatty acids and prevents the postprandial increase in complement component 31-3. Am J Clin Nutr 79 (2004) 5-10
32. Rollins B.J., Walz A., and Baggiolini M. Recombinant human MCP-1/JE induces chemotaxis, calcium flux, and the respiratory burst in human monocytes. Blood 78 (1991) 1112-1116
33. Weisberg S.P., McCann D., Desai M., et al. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 112 (2003) 1796-1808
34. Gao Z., Zhang X., Zuberi A., et al. Inhibition of insulin sensitivity by free fatty acids requires activation of multiple serine kinases in 3T3-L1 adipocytes. Mol Endocrinol 18 (2004) 2024-2034
35. Medzhitov R. Toll-like receptors and innate immunity. Nat Rev Immunol 1 (2001) 135-145
36. Ozcan U., Cao Q., Yilmaz E., et al. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science 306 (2004) 457-461
37. Hirasawa A., Tsumaya K., Awali T., et al. Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR 120. Nat Med 1 (2005) 90-94
38. Itoh Y., Kawamata Y., Harada M., et al. Free fatty acids regulate insulin secretion from pancreatic beta cells through GPR40. Nature 422 (2003) 173-176
39. Boden G. Free fatty acids and insulin secretion in humans. Curr Diab Rep 5 (2005) 167-170
40. Benjamin S.M., Valdez R., Geiss L.S., et al. Estimated number of adults with prediabetes in the US in 2000: opportunities for prevention. Diabetes Care 26 (2003) 645-649
41. Bamba V., and Rader D.J. Obesity and atherogenic dyslipidemia. Gastroenterology 132 (2007) 2181-2190
42. Boden G., and Rao A.K. Effects of hyperglycemia and hyperinsulinemia on the tissue factor pathway of blood coagulation. Curr Diab Rep 7 (2007) 223-227
43. Boden G., Vaidyula V.R., Homko C., et al. Circulating tissue factor procoagulant activity and thrombin generation in patients with type 2 diabetes: Effects of insulin and glucose. J Clin Endocrinol Metab 92 (2007) 4352-4358
44. Vague P., Juhan-Vague I., Aillaud M.F., et al. Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level and relative body weight in normal and obese subjects. Metabolism 35 (1986) 250-253
45. Pannacciulli N., De Mitrio R., Giorgino R., et al. Effect of glucose tolerance status on PAI-1 plasma levels in overweight and obese subjects. Obes Res 10 (2002) 717-725
46. Festa A., D'Agostino Jr. R., Tracy R.P., et al. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes 51 (2002) 1131-1137
47. Sobel B.E., and Schneider D.J. Platelet function, coagulopathy, and impaired fibrinolysis in diabetes. Cardiol Clin 22 (2004) 511-526
48. Hennekens C.H. Increasing burden of cardiovascular disease: current knowledge and future directions for research on risk factors. Circulation 97 (1998) 1095-1102
49. Newby A.C. Dual role of matrix metalloproteinases (Matrixins) in intimal thickening of atherosclerotic plaque rupture. Physiol Rev 85 (2005) 1-31
50. Galis Z.S., Sukhova G.K., Lark M.W., et al. Increased expression of matrix metallo-proteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 94 (1994) 2493-2503
51. Pasterkamp G., Schoneveld A.H., Hijnen D.J., et al. Atherosclerotic arterial remodeling and the localization of macrophages and matrix metalloproteinases 1, 2 and 9 in the human coronary artery. Atherosclerosis 150 (2000) 245-253
52. Longo G.M., Xiong W., Greiner T.C., et al. Matrix metalloproteinases 2 and 9 work in concert to produce aortic aneurysms. J Clin Invest 110 (2002) 625-632
53. Boden G., Song W., Pashko L., et al. In vivo effects of insulin and free fatty acids on matrix metalloproteinases in rat aorta. Diabetes 57 (2008) 476-483
54. Chen X., Iqbal N., and Boden G. The effects of free fatty acids on gluconeogenesis and glycogenolysis in normal subjects. J Clin Invest 103 (1999) 365-372
55. Boden G., Homko C., Mozzoli M., et al. Thiazolidinediones upregulate fatty acid uptake and oxidation in adipose tissue of diabetic patients. Diabetes 54 (2005) 880-885
56. Ghazzi M.N., Perez J.E., Antonucci T.K., et al. Cardiac and glycemic benefits of troglitazone treatment in NIDDM: the Troglitazone Study Group. Diabetes 46 (1997) 433-439
57. Maggs D.G., Buchanan T.A., Burant C.F., et al. Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 128 (1998) 176-185
58. Boden G., and Zhang M. Recent findings concerning thiazolidinediones in the treatment of diabetes. Expert Opin Investig Drugs 15 (2006) 243-250
59. Staels B., and Fruchart J.-C. Therapuetic roles of peroxisome proliferator-activated receptor agonists. Diabetes 54 (2005) 2460-2470
60. Boden G., Homko C., Mozzoli M., et al. Combined use of rosiglitazone and fenofibrate in patients with type 2 diabetes. Prevention of fluid retention. Diabetes 56 (2007) 248-255